Clinical study of protein iron succinate oral liquid in treating anemia secondary to abnormal uterine bleeding
Objective To explore the efficacy and safety of iron protein succinate oral liquid in the treatment of anemia secondary to abnormal uterine bleeding in women.Methods Totally 150 patients,who were diagnosed with secondary anemia due to abnormal uterine bleeding in the Department of Gynecology of the First Affiliated Hospital of Heilongjiang University of Chinese Medicine from April 2021 to September 2022,were included in the study.All patients were treated with protein iron succinate oral solution(Sheng Xueyuan)on the basis of symptomatic hemostasis treatment.The clinical total effective rate,changes in efficacy indicators such as hemoglobin,serum iron,serum ferritin,and the incidence of ad-verse reactions were observed in the second and fourth weeks after treatment.Results The total clinical effective rate was 75.3%after 2 weeks of treatment,and 90.4%after 4 week of treatment(x2=1 1.680,P<0.05).After treatment,hemo-globin,serum iron,and serum ferritin increased significantly compared with those before treatment(P<0.05),and total iron binding force decreased significantly compared with those before treatment(P<0.05),and the recovery of various indicators at 4 weeks of treatment was significantly higher than that at 2 weeks of treatment.No adverse reactions oc-curred after treatment.Conclusion Protein iron succinate oral liquid has good efficacy and safety in the treatment of secondary anemia caused by gynecological abnormal uterine bleeding,and is worthy of clinical promotion.
protein iron succinate oral liquidabnormal uterine bleedingsecondary anemiahemoglobinserum ironse-rum ferritinsafety